Colinz Laboratories FY26 results: BSE filing update

What the BSE filing is about

Colinz Laboratories Limited has completed a key compliance step with the Bombay Stock Exchange by submitting newspaper clippings of its FY26 audited financial results. The filing was made under Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company said the results were published in two newspapers, Free Press Journal and Navshakti, on April 30, 2026. This submission was addressed to BSE’s Corporate Relations Department.

The compliance relates to audited financial results for the quarter and year ended March 31, 2026. Colinz Laboratories stated these audited results were approved by the Board of Directors on April 29, 2026, before being published the next day. The company’s BSE scrip code is 531210.

Who submitted the document and when

The filing was submitted by Additional Director Vijaya Mani (DIN: 11363910). The submission date mentioned is April 30, 2026, matching the publication date of the newspaper advertisements. The stated purpose of the submission was to place the newspaper clippings on record with the exchange, as required by the disclosure norms.

In line with exchange practice, the company also noted that the full set of financial results is accessible on BSE’s website (www.bseindia.com) and the company’s website. This disclosure is meant to ensure broad investor access, beyond the exchange filing.

FY26 audited results: key numbers disclosed

Colinz Laboratories’ FY26 audited results include both quarterly and annual performance figures. One set of figures mentions Q4 FY26 revenue of ₹1.9224 crore (₹192.24 lakh) and net profit of ₹0.1712 crore (₹17.12 lakh). The same disclosure also mentions annual revenue of ₹6.6205 crore (₹662.05 lakh) and annual net profit of ₹0.5145 crore (₹51.45 lakh).

Separately, the company also reported that for the fiscal year ended March 31, 2026, revenue from operations stood at ₹6.1361 crore (₹613.61 lakh) and profit for the period was ₹0.5145 crore (₹51.45 lakh). The company described this as a marginal increase in profit from the previous year, while noting a year-on-year decline in revenue from operations.

Quarter-on-quarter and year-on-year comparison cited

The disclosed comparison states Q4 FY26 revenue rose to ₹1.7479 crore (₹174.79 lakh) from ₹1.4514 crore (₹145.14 lakh) in Q4 FY25. Profit for Q4 FY26 was reported at ₹0.1712 crore (₹17.12 lakh), compared with ₹0.1504 crore (₹15.04 lakh) in Q4 FY25.

For the full year, revenue from operations for FY26 was stated at ₹6.1361 crore (₹613.61 lakh), down from ₹6.5277 crore (₹652.77 lakh) in FY25. Profit for the period increased to ₹0.5145 crore (₹51.45 lakh) from ₹0.4966 crore (₹49.66 lakh) year-on-year.

Audit opinion and board-level review

Colinz Laboratories stated that the FY26 financial results received an unqualified or unmodified audit opinion from the statutory auditors. The auditors named in the disclosure are Vora & Associates. The company also stated that the Audit Committee reviewed the results before the Board approved them.

Such sequencing is important in the context of listed-company governance, where audit committee review and board approval typically precede publication and stock exchange submissions.

Related party transaction disclosure: company’s position

Alongside the FY26 results-related disclosures, Colinz Laboratories declared non-applicability of the Related Party Transaction disclosure requirements for Q4 FY26 under SEBI LODR Regulation 23(9). The company stated to BSE that it is not required to comply with the related party transaction disclosure requirements for the quarter ended March 31, 2026.

This clarification is often filed to close out compliance expectations for the reporting period, especially where the regulation is not applicable due to thresholds or other conditions, as stated by the company.

Context from earlier exchange filings

The material also refers to a separate submission for unaudited financial results for the quarter ending December 31, 2025, approved by the Board on January 24, 2026. That filing indicated revenue of ₹15.095 crore (₹150.95 million) and net profit after tax of ₹0.836 crore (₹8.36 million) for the quarter, as stated in the document.

In addition, historical annual report figures for FY25 show total revenue of ₹6.8256 crore (₹682.56 lakh) compared with ₹7.3046 crore (₹730.46 lakh) in FY24, with FY25 profit for the year at ₹0.4966 crore (₹49.66 lakh).

Key facts at a glance

Financial snapshot (all amounts in ₹ crore)

Why this filing matters for investors

For shareholders and market participants, the submission of newspaper clippings is mainly a compliance confirmation rather than a new financial event. But it reinforces that the audited FY26 results were formally published and filed in the manner required under SEBI’s listing framework. It also provides a clear paper trail: audit committee review, board approval, publication, and exchange submission.

The disclosures also help investors reconcile performance across periods. The company has reported a year-on-year decline in revenue from operations for FY26 versus FY25, while profit for the period increased slightly. Separately, the Q4 comparison disclosed shows higher revenue and profit versus the same quarter of the prior year.

Conclusion

Colinz Laboratories’ April 30, 2026 submission to BSE completes the Regulation 47(3) publication compliance for its FY26 audited results. The filing also reiterates the company’s audited profit and revenue figures for Q4 and the full year ended March 31, 2026, and its stated non-applicability under Regulation 23(9) for Q4 FY26. Investors can access the full audited results through the BSE portal and the company’s website, as disclosed.